[1] González C,Bonilla S,Flores AI, et al. An Update on Human Stem Cell-based Therapy in Parkinson's Disease.Curr Stem Cell Res Ther. 2015 May 31. [Epub ahead of print].
[2] Roger A, Barker, Drouin-Ouellet J, et al. Cell‐based therapies for Parkin-son disease-past insights and future potential.Nature Reviews Neurology. 2015; 11:492-503.
[3] Cao L,TanL,Jiang T,et al. Induced Pluripotent Stem Cells for Disease Model-ing and Drug Discovery in Neurodegenerative Diseases.Molecular Neurobiol-ogy. 2015;52(1):244-255.
[4] Takahashi K,Yamanaka S. Induction of pluripotent stem cells from mouse em-bryonic and adult fibroblast cultures by defined factors. Cell.2006;126(4): 663-676.
[5] Rhee YH, Ko JY, Chang MY, et al. Protein-based human iPS cells efficiently generate functional dopamine neurons and can treat a rat model of Parkinson disease.J Clin Invest. 2011 Jun; 121(6): 2326-2335.
[6] Soldner F, Hockemeyer D, Beard C, et al. Parkinson’s disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell.2009;136(5): 964-977.
[7] Perrier AL, Tabar V, Barberi T, et al. Derivation of midbrain dopamine neurons from human embryonic stem cells. ProcNatlAcadSci U S A .2004;101: 12543-12548.
[8] Yang D, Zhang ZJ, Oldenburg M, et al. Human embryonic stem cell-derived dopaminergic neurons reverse functional deficit in parkinsonian rats. Stem Cells.2008;26:55-63.
[9] Chambers SM,Fasano CA,Papapetrou EP,et al.Highly efficient neural conver-sion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Bio-technol. 2009;27:275-280.
[10] Cooper O, Hargus G, Deleidi M,et al. Differentiation of human ES and Parkin-son's disease iPS cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid.Mol Cell Neurosci. 2010;45(3):258-266.
[11] Sundberg M, Bogetofte H, Lawson T, et al. Improved cell therapy protocol for Parkinson’s disease based on differentiation efficiency and safety of hESC-, hiPSC and non-human primate iPSC-derived DA neurons. Stem Cells.2013;31(8):1548-1562.
[12] Kwon YW, Chung YJ, Kim J, et al.Comparative Study of Efficacy of Dopaminer-gic Neuron Differentiation between Embryonic Stem Cell and Protein-Based In-duced Pluripotent Stem Cell.PLoS One.2014; 9(1): e85736.
[13] Kikuchi T, Morizane A, Doi D, et al. Survival of Human Induced Pluripotent Stem Cell-Derived Midbrain Dopaminergic Neurons in the Brain of a Primate Model of Parkinson’s Disease.J Parkinsons Dis. 2011;1(4): 395-412.
[14] Han F, Wang W, Chen B, et al. Human induced pluripotent stem cellederived neurons improve motor asymmetry in a 6-hydroxydopamineeinduced rat model of Parkinson’s disease. Cytotherapy.2015; 17(5): 665-679.
[15] Santana M, Palmér T, Simplício H, et al. Characterization of long-term motor deficits in the 6- OHDAmodel of Parkinson’s disease in the common marmoset. Behav Brain Res.2015;290:90-101.
[16] Franke SK, van Kesteren RE, Wubben JA, et al. Progression and re-covery of parkinsonism in a chronic progressive MPTP-induction model in the marmoset without persistent molecular and cellular damage. Neuroscience.2016;312:247-259.
[17] Samata B, Kikuchi T, Miyawaki Y, et al. X-linked severe combined immunodefi-ciency (X-SCID) rats for xeno-transplantation and behavioral evaluation.J Neu-rosci Methods. 2015;243:68-77.
[18] Hargus G, Cooper O, Deleidi M, et al. Differentiated Parkinson pa-tient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats.ProcNatlAcadSci U S A,2010;107(36):15921-15926.
[19] Doi D, Samata B, Katsukawa M, et al. Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation. Stem Cell Rep.Stem Cell Reports. 2014;2(3):337-350.
[20] Ganat YM, Calder EL, Kriks S, et al. Identification of embryonic stem cell-derived midbrain dopaminergic neurons for engraftment.JClin In-vest.2012;122(8): 2928-2939.
[21] Grealish S,Diguet E,Kirkeby A,et al. Human ESC-derived dopamine neurons show similar preclinical efficacy and potency to fetal neurons when grafted in a rat model of Parkinson's disease.Cell Stem Cell.2014;15(5):653-665.
[22] LindvallO.Treatment of Parkinson's disease using cell transplantation. Philos Trans R SocLond B Biol Sci. 2015;370(1680).
[23] Marei HE, Lashen S, Farag A, et al.Human olfactory bulb neural stem cells mitigate movement disorders in a rat model of Parkinson's disease.J Cell Physiol.2015; 230(7):1614-1629.
[24] Rumpel R, Hohmann M, Klein A, et al.Transplantation of fetal ventral mesencephalic progenitor cells overexpressing high molecular weight fibroblast growth factor 2 isoforms in 6-hydroxydopamine lesione-drats.Neuroscience.2015;286:293-307.
[25] Müller J, Ossig C, Greiner JF,et al.Intrastriatal transplantation of adult human neural crest-derived stem cells improves functional outcome in parkin-sonianrats. Stem Cells Transl Med.2015; 4(1): 31-43.
[26] Takagi Y,Takahashi J,Saiki H,et al.Dopamin- ergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model.J Clin In-vest. 2005;115:102-109.
[27] Saiki H, Hayashi T, Takahashi R, et al. Objective and quantitative evalua-tion of motor function in a monkey model of Parkinson’s disease. J Neurosci Methods, 2010;190:198-204.
[28] Hallett PJ, Deleidi M, Astradsson A, et al. Successful Function of Autologous iPSC-Derived Dopamine Neurons following Transplantation in a Non-Human Primate Model of Parkinson’s Disease.Cell Stem Cell, 2015;16:269-274.
[29] Vitte J, Traver S, Maués De Paula A, et al. Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumu-lates in the core of Lewy bodies in Parkinson disease. J NeuropatholExp Neu-rol.2010;69:959-972.
[30] Miki Y, Mori F, Tanji K,et al. Accumulation of histone deacetylase 6, an aggresome-related protein, is specific to Lewy bodies and glial cytoplasmic inclusions. Neuropathology.2011;31:561-568.
[31] Tanikawa S, Mori F, Tanji K, et al. Endosomal sorting related protein CHMP2B is localized in Lewy bodies and glial cytoplasmic inclusions in alpha-synucleinopathy. Neurosci Lett.2012;527:16-21.
[32] Shults CW. Lewybodies.ProcNatlAcadSci U S A.2006; 103:1661-1668.
[33] Maroteaux L, Campanelli JT, Scheller RH, et al. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J.Neurosci. 1988; 8:2804-2815.
[34] Lesage S, Anheim M, Letournel F, et al.G51D alpha-synuclein mutation causes a novelparkinsonian- pyramidal syndrome.Ann Neurol. 2013;73:459-471.
[35] Recasens A, Dehay B.Alpha-synuclein spreading in parkinson’s disease. Front Neuroanat.2014;8:159.
[36] Braak H, Del Tredici K, et al.Staging of brain pathology related to spo-radic Parkinson’s disease.Neurobiol Aging.2003;24:197-211.
[37] Navarro-Otano J, Gelpi E, Mestres CA,et al. Alpha-synuclein aggregates in epicardial fat tissue in living subjects without parkinsonism. Parkinsonism Relat. Disord.2013;19:27-31.
[38] Gelpi E, Navarro-Otano J, Tolosa E, et al. Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders.Mov Disord.2014;29:1010-1018.
[39] Brundin P, Li JY, Holton JL,et al.Research in motion: the enigma of Park-inson’s disease pathology spread. Nat RevNeurosci.2008; 9: 741-745.
[40] Mendez I, Viñuela A, Astradsson A, et al. Dopamine neurons implanted into people with Parkinson’s disease survive without pathology for 14 years.Nat Med.2008;14:507-509. |